Results 51 to 60 of about 12,210 (151)

Neovascular age‐related macular degeneration without drusen

Acta Ophthalmologica, Volume 104, Issue 3, Page e300-e311, May 2026.
Abstract Purpose To describe the clinical characteristics and 1‐year follow‐up of patients with neovascular AMD (nAMD) without drusen in either eye. Methods This is a multicentre retrospective cohort study in three tertiary referral centres in The Netherlands. We included patients of 55 years or older with nAMD in one or both eyes, without the presence
Marc J. Sirks, Elon H. C. van Dijk, Husein Ghalayini, Somayeh Bazdar, WeiFeng Yu, Suzanne Yzer, José P. Martinez Ciriano, Reinier O. Schlingemann, Roselie M. H. Diederen, Camiel J. F. Boon   +9 more
wiley   +1 more source

Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context

BMC Ophthalmology, 2018
Background To compare anti-VEGF treatments for macular disease in terms of costs and clinical outcomes. Methods We identified patients suffering from macular disease and treated either with aflibercept, ranibizumab or both at the largest public eye ...
Martin K. Schmid, Oliver Reich, Eva Blozik, Livia Faes, Nicolas S. Bodmer, Silvan Locher, Michael A. Thiel, Roland Rapold, Maximilian Kuhn, Lucas M. Bachmann   +9 more
doaj   +1 more source

Twelve‐Month Real‐World Outcomes of Faricimab for Treatment‐Naive Neovascular AMD in Australia

Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 500-506, May/June 2026.
ABSTRACT Background To provide insights into the effectiveness and safety of faricimab for treatment‐naïve eyes with neovascular age‐related macular degeneration (nAMD). Methods A retrospective cohort study using a prospectively‐designed registry. Treatment‐naïve eyes with nAMD in Australia starting treatment with faricimab between Jan 2023–Sep 2024 ...
Mark Gillies, Yohei Hashimoto, Rahman Nazari, Jennifer Arnold, Beibei Wang, Richard Barry, Ross Ferrier, Justin Game, Daniel Barthelmes   +8 more
wiley   +1 more source

Treatment of age-related macular degeneration: focus on ranibizumab

Clinical Ophthalmology, 2008
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter SzurmanTuebingen University Eye Center, University of Tuebingen, GermanyAbstract: Ranibizumab, a humanized antigen-binding fragment (Fab) that binds all isoforms of VEGF-A ...
Martin S Spitzer, Focke Ziemssen, Karl U Bartz-Schmidt, Faik Gelisken, Peter Szurman   +4 more
doaj  

Prognostic Factors in Patients With Submacular Haemorrhage Complicating Age‐Related Macular Degeneration: A Post Hoc Analysis of the STAR Study

Clinical &Experimental Ophthalmology, Volume 54, Issue 4, Page 492-499, May/June 2026.
ABSTRACT Background To investigate prognostic factors of recent submacular haemorrhage (SMH) complicating neovascular age‐related macular degeneration (nAMD) treated with surgery or pneumatic displacement combined with intravitreal injection of anti‐vascular endothelial growth factor.
Pierre‐Henry Gabrielle, Petra Eid, Ludwig Serge Aho, Laurent Kodjikian, Eric Souied, Joel Uzzan, Jean Baptiste Conart, Marie‐Noëlle Delyfer, Catherine Creuzot‐Garcher   +8 more
wiley   +1 more source

The efficacy of ranibizumab treatment in clinical practice in patients with the wet form of age-related macular degeneration. The results of the Czech National Registry

Biomedical Papers, 2015
Aims: The aim of this communication was to evaluate ranibizumab in the treatment of wet age-related macular degeneration. Methods: Anonymised data on treatment efficacy and safety were consecutively entered into the Czech national database.
Oldrich Chrapek, Jiri Jarkovsky, Jan Studnicka, Martin Sin, Petr Kolar, Barbora Jirkova, Ladislav Dusek, Sarka Pitrova, Jiri Rehak   +8 more
doaj   +1 more source

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, EarlyView.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema

Clinical Interventions in Aging, 2013
Angie HC Fong,1 Timothy YY Lai1,2 1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong; 22010 Retina and Macula Centre, Tsimshatsui, Kowloon, Hong Kong Abstract: Neovascular ...
Fong AH, Lai TY
doaj  

Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective

ClinicoEconomics and Outcomes Research, 2015
Stephane A Régnier,1 William Malcolm,2 Jennifer Haig,3 Weiguang Xue41Novartis Pharma AG, Basel, Switzerland; 2Novartis Pharmaceuticals UK Ltd, Frimley Business Park, UK; 3Optum, Burlington, ON, Canada; 4Optum, Uxbridge, UKBackground: Ranibizumab ...
Régnier SA, Malcolm W, Haig J, Xue W   +3 more
doaj  

Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration:a systematic review and meta-analysis of randomized controlled trials

International Journal of Ophthalmology, 2014
AIM:To compare the efficacy and safety of combination of ranibizumab with photodynamic therapy (PDT) vs ranibizumab monotherapy in the treatment of age-related macular degeneration (AMD).METHODS:The Cochrane Central Register of Controlled Trials (CENTRAL)
Jun-Kang Si, Kai Tang, Hong-Sheng Bi, Da-Dong Guo, Jun-Guo Guo, Yu-Xiang Du, Yan Cui, Xue-Mei Pan, Ying Wen, Xing-Rong Wang   +9 more
doaj   +1 more source